Who are ClearB Therapeutics's investors?

ClearB Therapeutics's investors include Morningside Group.

When was ClearB Therapeutics founded?

ClearB Therapeutics was founded in 2017.

Where is ClearB Therapeutics headquartered?

ClearB Therapeutics is headquartered in Concord, Massachusetts, United States.

What industry is ClearB Therapeutics in?

ClearB Therapeutics operates in Biotech, Healthcare.

How many employees does ClearB Therapeutics have?

ClearB Therapeutics has 1-10 employees.

ClearB Therapeutics

Developing a functional cure for hepatitis B

Concord, United States · Founded 2017

Biotech

Healthcare

Headquarters: Concord, Massachusetts
Employees: 1–10
Founded: 2017
Business Model: B2B

Website: clearbtherapeutics.com
Last Round: SeedJan 2017
Rounds: 1

About

ClearB Therapeutics is a clinical-stage biotechnology company developing immune-based therapies designed to achieve a functional cure for chronic hepatitis B (CHB), a disease affecting over 250 million people worldwide. Co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victorian Infectious Diseases Reference Laboratory (VIDRL) in Melbourne, Australia, ClearB's science is grounded in proprietary insights into how hepatitis B surface antigens can be targeted to redirect the patient's immune system. The company's lead program, CLB-3000, is a therapeutic vaccine in Phase 1b clinical trials. ClearB also has CLB-4000, a second candidate for which a sentinel safety cohort has been evaluated in a first-in-human study. The company is funded by Morningside Ventures and is headquartered in Concord, Massachusetts, with scientific roots in Australia.

Summary

ClearB Therapeutics is a Biotech company based in Concord, United States, founded in 2017. Its most recent funding was a Seed round in Jan 2017. Investors include Morningside Group.